^
    Back
    Association details:
    Biomarker:DDR2 S768R
    Cancer:Lung Non-Small Cell Squamous Cancer
    Drug:erlotinib (EGFR inhibitor) +
    dasatinib (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Cancer Discov
    Title:

    Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer

    Excerpt:
    The patient was a 59 year old Caucasian woman...began combination dasatinib and erlotinib therapy on protocol. A restaging CT scan after nearly 2 months indicated tumor shrinkage and the patient experienced improved symptoms (resolved dyspnea and cough) (Figures 5A and 5B).
    DOI:
    10.1158/2159-8274.CD-11-0005